AXSM
HealthcareAxsome Therapeutics, Inc.
$154.91+0.79 (+0.51%)
Prev Close
$154.12
Open
$154.55
High
$157.75
Low
$153.66
Volume
493.9K
Market Cap
$8.36B
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Axsome Therapeutics, Inc. (AXSM) has been dominated by selling, with 1 insider purchase totaling $200.5K and 26 insider sales totaling $161.94M. The most recent insider transaction was by Coleman Mark (director), who sold $4.03M worth of shares on Feb 27, 2026. Axsome Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $8.36B.
Buys (12M)
1
$200.5K
Sells (12M)
26
$161.94M
Net Activity
Net Seller
$161.74M
Active Insiders
9
last 12 mo
AXSM Price Chart
AXSM Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026↗ | Coleman Mark | director | Sell | 25,000 | $161.11 | $4.03M | 47,140 |
| Feb 27, 2026↗ | Jacobson Mark L. | officer: Chief Operating Officer | Sell | 35,378 | $161.88 | $5.73M | 0 |
| Feb 2, 2026↗ | TABUTEAU HERRIOT | director, 10 percent owner, officer: Chief Executive Officer | Sell | 64,820 | $185.60 | $12.03M | 7,229 |
| Jan 23, 2026↗ | Maizel Ari | officer: Chief Commercial Officer | Sell | 7,500 | $184.44 | $1.38M | 0 |
| Jan 23, 2026↗ | Pizzie Nick | officer: Chief Financial Officer | Sell | 12,000 | $187.92 | $2.26M | 42,588 |
| Jan 22, 2026↗ | Pizzie Nick | Chief Financial Officer | Sell | 12,000 | $187.92 | $2.26M | 0 |
| Jan 21, 2026↗ | Maizel Ari | Chief Commercial Officer | Sell | 7,500 | $184.44 | $1.38M | 0 |
| Jan 7, 2026↗ | TABUTEAU HERRIOT | director, 10 percent owner, officer: Chief Executive Officer | Sell | 139,414 | $171.30 | $23.88M | 7,229 |
| Jan 5, 2026↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 139,414 | $171.30 | $23.88M | 0 |
| Dec 31, 2025↗ | Saad Mark E | Director | Sell | 37,577 | $165.18 | $6.21M | 0 |
| Dec 2, 2025↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 79,973 | $145.66 | $11.65M | 0 |
| Nov 3, 2025↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 163,939 | $133.07 | $21.82M | 0 |
| Oct 6, 2025↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 45,384 | $119.38 | $5.42M | 0 |
| Sep 22, 2025↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 10,000 | $115.96 | $1.16M | 0 |
| Sep 16, 2025↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 45,783 | $114.48 | $5.24M | 0 |
| Sep 12, 2025↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 62,880 | $117.08 | $7.36M | 0 |
| Sep 8, 2025↗ | Coleman Mark | Director | Buy | 1,575 | $127.28 | $200.5K | 0 |
| Sep 5, 2025↗ | Saad Mark E | Director | Sell | 9,127 | $125.07 | $1.14M | 0 |
| Sep 2, 2025↗ | JEFFS ROGER | Director | Sell | 13,464 | $123.68 | $1.67M | 0 |
| Aug 27, 2025↗ | JEFFS ROGER | Director | Sell | 60,000 | $121.72 | $7.30M | 0 |
| Aug 22, 2025↗ | JEFFS ROGER | Director | Sell | 36,694 | $120.05 | $4.41M | 0 |
| Jun 20, 2025↗ | Murdock Hunter R. | General Counsel | Sell | 13,514 | $101.42 | $1.37M | 0 |
| Jun 16, 2025↗ | Murdock Hunter R. | General Counsel | Sell | 22,500 | $101.19 | $2.28M | 0 |
| Jun 9, 2025↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 25,000 | $110.44 | $2.76M | 0 |
| May 27, 2025↗ | Coleman Mark | Director | Sell | 7,500 | $104.45 | $783.4K | 0 |
| May 27, 2025↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 40,673 | $104.07 | $4.23M | 0 |
| May 20, 2025↗ | Coleman Mark | Director | Sell | 3,000 | $107.49 | $322.5K | 0 |
| Feb 13, 2025↗ | Pizzie Nick | Chief Financial Officer | Sell | 15,000 | $130.10 | $1.95M | 0 |
| Aug 9, 2024↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 47,739 | $84.26 | $4.02M | 0 |
| May 29, 2024↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 7,910 | $74.31 | $587.8K | 0 |
| May 28, 2024↗ | Coleman Mark | Director | Sell | 10,497 | $75.17 | $789.1K | 0 |
| Apr 1, 2024↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 24,662 | $77.24 | $1.90M | 0 |
| Mar 14, 2024↗ | JEFFS ROGER | Director | Sell | 32,323 | $69.84 | $2.26M | 0 |
| Sep 15, 2023↗ | Coleman Mark | Director | Sell | 29,588 | $75.18 | $2.22M | 0 |
| Nov 19, 2021↗ | JEFFS ROGER | Director | Buy | 3,950 | $37.30 | $147.3K | 0 |
| Nov 18, 2021↗ | Coleman Mark | Director | Buy | 1,430 | $35.09 | $50.2K | 0 |
| Nov 18, 2021↗ | Pizzie Nick | CHIEF FINANCIAL OFFICER | Buy | 955 | $35.26 | $33.7K | 0 |
| Nov 17, 2021↗ | Saad Mark E | Director | Buy | 3,300 | $34.52 | $113.9K | 0 |
| May 12, 2021↗ | Coleman Mark | Director | Buy | 500 | $58.15 | $29.1K | 0 |
AXSM Insider Buying Activity
The following table shows recent insider purchases of Axsome Therapeutics, Inc. (AXSM) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 8, 2025↗ | Coleman Mark | Director | Buy | 1,575 | $127.28 | $200.5K | 0 |
| Nov 19, 2021↗ | JEFFS ROGER | Director | Buy | 3,950 | $37.30 | $147.3K | 0 |
| Nov 18, 2021↗ | Coleman Mark | Director | Buy | 1,430 | $35.09 | $50.2K | 0 |
| Nov 18, 2021↗ | Pizzie Nick | CHIEF FINANCIAL OFFICER | Buy | 955 | $35.26 | $33.7K | 0 |
| Nov 17, 2021↗ | Saad Mark E | Director | Buy | 3,300 | $34.52 | $113.9K | 0 |
| May 12, 2021↗ | Coleman Mark | Director | Buy | 500 | $58.15 | $29.1K | 0 |
AXSM Insider Selling Activity
The following table shows recent insider sales of Axsome Therapeutics, Inc. (AXSM) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 27, 2026↗ | Coleman Mark | director | Sell | 25,000 | $161.11 | $4.03M | 47,140 |
| Feb 27, 2026↗ | Jacobson Mark L. | officer: Chief Operating Officer | Sell | 35,378 | $161.88 | $5.73M | 0 |
| Feb 2, 2026↗ | TABUTEAU HERRIOT | director, 10 percent owner, officer: Chief Executive Officer | Sell | 64,820 | $185.60 | $12.03M | 7,229 |
| Jan 23, 2026↗ | Maizel Ari | officer: Chief Commercial Officer | Sell | 7,500 | $184.44 | $1.38M | 0 |
| Jan 23, 2026↗ | Pizzie Nick | officer: Chief Financial Officer | Sell | 12,000 | $187.92 | $2.26M | 42,588 |
| Jan 22, 2026↗ | Pizzie Nick | Chief Financial Officer | Sell | 12,000 | $187.92 | $2.26M | 0 |
| Jan 21, 2026↗ | Maizel Ari | Chief Commercial Officer | Sell | 7,500 | $184.44 | $1.38M | 0 |
| Jan 7, 2026↗ | TABUTEAU HERRIOT | director, 10 percent owner, officer: Chief Executive Officer | Sell | 139,414 | $171.30 | $23.88M | 7,229 |
| Jan 5, 2026↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 139,414 | $171.30 | $23.88M | 0 |
| Dec 31, 2025↗ | Saad Mark E | Director | Sell | 37,577 | $165.18 | $6.21M | 0 |
| Dec 2, 2025↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 79,973 | $145.66 | $11.65M | 0 |
| Nov 3, 2025↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 163,939 | $133.07 | $21.82M | 0 |
| Oct 6, 2025↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 45,384 | $119.38 | $5.42M | 0 |
| Sep 22, 2025↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 10,000 | $115.96 | $1.16M | 0 |
| Sep 16, 2025↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 45,783 | $114.48 | $5.24M | 0 |
| Sep 12, 2025↗ | TABUTEAU HERRIOT | Chief Executive Officer | Sell | 62,880 | $117.08 | $7.36M | 0 |
| Sep 5, 2025↗ | Saad Mark E | Director | Sell | 9,127 | $125.07 | $1.14M | 0 |
| Sep 2, 2025↗ | JEFFS ROGER | Director | Sell | 13,464 | $123.68 | $1.67M | 0 |
| Aug 27, 2025↗ | JEFFS ROGER | Director | Sell | 60,000 | $121.72 | $7.30M | 0 |
| Aug 22, 2025↗ | JEFFS ROGER | Director | Sell | 36,694 | $120.05 | $4.41M | 0 |
| Jun 20, 2025↗ | Murdock Hunter R. | General Counsel | Sell | 13,514 | $101.42 | $1.37M | 0 |
| Jun 16, 2025↗ | Murdock Hunter R. | General Counsel | Sell | 22,500 | $101.19 | $2.28M | 0 |
| Jun 9, 2025↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 25,000 | $110.44 | $2.76M | 0 |
| May 27, 2025↗ | Coleman Mark | Director | Sell | 7,500 | $104.45 | $783.4K | 0 |
| May 27, 2025↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 40,673 | $104.07 | $4.23M | 0 |
| May 20, 2025↗ | Coleman Mark | Director | Sell | 3,000 | $107.49 | $322.5K | 0 |
| Feb 13, 2025↗ | Pizzie Nick | Chief Financial Officer | Sell | 15,000 | $130.10 | $1.95M | 0 |
| Aug 9, 2024↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 47,739 | $84.26 | $4.02M | 0 |
| May 29, 2024↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 7,910 | $74.31 | $587.8K | 0 |
| May 28, 2024↗ | Coleman Mark | Director | Sell | 10,497 | $75.17 | $789.1K | 0 |
| Apr 1, 2024↗ | Jacobson Mark L. | Chief Operating Officer | Sell | 24,662 | $77.24 | $1.90M | 0 |
| Mar 14, 2024↗ | JEFFS ROGER | Director | Sell | 32,323 | $69.84 | $2.26M | 0 |
| Sep 15, 2023↗ | Coleman Mark | Director | Sell | 29,588 | $75.18 | $2.22M | 0 |
AXSM Insiders
TABUTEAU HERRIOT
director, 10 percent owner, officer: Chief Executive Officer
Sold $29.90M
4 tradesLast: Feb 2, 2026
Similar Stocks to AXSM
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B